Current Edition


Bavarian Nordic Announces Initiation of Phase 2 Trial Evaluating the Combination Therapy of CV301 and Nivolumab in Metastatic Colorectal Cancer

Investigator-led study has commenced dosing Immunotherapy candidate CV301 is being assessed in combination with checkpoint inhibitors in multiple solid tumors Bavarian Nordic A/S (OMX: BAVA, …

Continue Reading →

Rapid Medical initiates TIGER Clinical Study

Data from the study will be submitted to the FDA in support of Market Clearance for TIGERTRIEVER in the U.S. Rapid Medical, an Israeli company …

Continue Reading →